Foundayo
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Foundayo?
Orforglipron tablets from Eli Lilly, FDA-approved April 2026 as the first oral non-peptide GLP-1 receptor agonist.
Taken daily on an empty stomach with a 30-minute wait. Its arrival matters commercially: a pill with no cold chain and no needle changes what a telehealth seller has to justify charging for.
How to take Foundayo (orforglipron) →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Foundayo comes up on this site
On GLP Watchdog, Foundayo comes up in 1 research article, 15 seller reviews and 4 tools.
Research that discusses it
Drug pages
Tools that use it
Seller reviews that mention it
Connected terms
Other terms under Drugs and brands
Where the evidence lives
- How to take Foundayo (orforglipron)
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers